Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

60.81
-0.4223-0.69%
Volume:111
Turnover:7K
Market Cap:9.12M
PE:- -
High:60.81
Open:61.23
Low:60.81
Close:61.23
52wk High:64.69
52wk Low:50.34
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.66
T/O Rate:0.07%
Dividend:0.51
Dividend Rate:0.84%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
2 hours ago

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
3 hours ago

Growth Without AI: 8 Stock Picks

Dow Jones
·
5 hours ago

Nextbiomedical Targets Global Investors at 2026 KIS BioTech Day

TIPRANKS
·
9 hours ago

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Dow Jones
·
10 hours ago

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
13 hours ago

GeoVax Updates Nasdaq Listing Amid Ongoing Clinical Progress

TIPRANKS
·
13 hours ago

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
14 hours ago

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
14 hours ago

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
16 hours ago

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
16 hours ago

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
18 hours ago

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Yesterday

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Yesterday

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Yesterday

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Yesterday

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Yesterday

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Yesterday

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Yesterday

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Yesterday